Improving Memory and Cognition in Individuals with Down Syndrome.
Down syndrome (DS), often due to trisomy 21, is the most common genetic cause of intellectual disability (ID). In addition, virtually all individuals with DS develop the neuropathology of Alzheimer's disease (AD) by the age of 40 years and almost 60 % will manifest symptoms of AD dementia by the age of 65 years. Currently, there are no pharmacological treatments available for ID in individuals with DS and only limited symptomatic treatments for AD dementia. Advances in our understanding in both the molecular basis of ID and the pathogenesis of AD have created opportunities to study potential therapeutic targets. Recent studies in animal models of DS continue to provide a rational basis for translating specific compounds into human clinical trials. However, target and compound selection are only initial steps in the drug development pathway. Other necessary considerations include appropriate study designs to assess efficacy in the DS population, as well as operational aspects specifically tailored to assess cognition in this population. We discuss recent progress in the development of compounds for both ID and AD in individuals with DS, as well as concepts for the design and conduct of clinical trials with such compounds.
Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive #0949, La Jolla, CA, 92093-0949, USA. mrafii@ucsd.edu.|Department of Neurology, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA. mrafii@ucsd.edu.
Michael S
MS
Rafii
D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003704:Dementia / Q000150:complications / Q000188:drug therapy*; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008568:Memory / Q000187:drug effects* / Q000502:physiology